Farrerol alleviates insulin resistance and hepatic steatosis of metabolic associated fatty liver disease by targeting PTPN1
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Jingwen Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Insulin Resistance, Protein Tyrosine Phosphatase, Non-Receptor Type 1. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the Science and Technology Plan of Suzhou City, Basic research pilot project of Suzhou.
Abstract (Originalsprache)
Metabolic associated fatty liver disease (MAFLD) is the most common chronic liver disease worldwide, characterized by excess lipid deposition. Insulin resistance (IR) serves as a fundamental pathogenic factor in MAFLD. However, currently, there are no approved specific agents for its treatment. Farrerol, a novel compound with antioxidant and anti‐inflammatory effects, has garnered significant attention in recent years due to its hepatoprotective properties. Despite this, the precise underlying mechanisms of action remain unclear. In this study, a network pharmacology approach predicted protein tyrosine phosphatase non‐receptor type 1 (PTPN1) as a potential target for farrerol's action in the liver. Subsequently, the administration of farrerol improved insulin sensitivity and glucose tolerance in MAFLD mice. Furthermore, farrerol alleviated lipid accumulation by binding to PTPN1 and reducing the dephosphorylation of the insulin receptor (INSR) in HepG2 cells and MAFLD mice. Thus, the phosphoinositide 3‐kinase/serine/threonine‐protein kinases (PI3K/AKT) signalling pathway was active, leading to downstream protein reduction. Overall, the study demonstrates that farrerol alleviates insulin resistance and hepatic steatosis of MAFLD by targeting PTPN1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- Suzhou Clinical Center of Digestive Diseases, Suzhou, China.
- Department of Endocrinology, Affiliated Hospital 2 of Nantong University and First People's Hospital of Nantong City, Nantong, China.
ORCID-Profile: Jingwen Gao, Xiaomin Cang, Chunfang Xu
Förderung
- National Natural Science Foundation of China
- the Science and Technology Plan of Suzhou City
- Basic research pilot project of Suzhou
- the Medical Research Project of Health Commission of Nantong
Zitieren
APA
Gao, J., Cang, X., Liu, L., Lin, J., Zhu, S., Liu, L., Liu, X., Zhu, J., & Xu, C. (2024). Farrerol alleviates insulin resistance and hepatic steatosis of metabolic associated fatty liver disease by targeting PTPN1. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70096
Vancouver
Gao J, Cang X, Liu L, Lin J, Zhu S, Liu L, et al. Farrerol alleviates insulin resistance and hepatic steatosis of metabolic associated fatty liver disease by targeting PTPN1. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70096
BibTeX
@article{Gao2024,
author = {Gao, Jingwen and Cang, Xiaomin and Liu, Lu and Lin, Jiaxi and Zhu, Shiqi and Liu, Lihe and Liu, Xiaolin and Zhu, Jinzhou and Xu, Chunfang},
title = {Farrerol alleviates insulin resistance and hepatic steatosis of metabolic associated fatty liver disease by targeting PTPN1},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70096}
}
EUVIMED